The experimental section of the Cancer Epigenetics Drug Database has been expanded to now include a fourth class of epigenetics-targeting drugs: the inhibitors of histone (lysine) demethylases or KDMi. This database currently includes data on 9 KDMi and 61 cancer cell lines. Together, the experimental section of the Cancer Epigenetics Drug Database now includes more than 3,500 experiments conducted on over 500 human cancer cell lines and over 30 functional assays. All four experimental databases may be accessed directly at https://ces.b2sg.org/cedd/ (Cancer Epigenetics Society news; November 7, 2016).